Intensity Therapeutics (INTS) Notes Payables (2022)
Intensity Therapeutics' (INTS) quarterly Notes Payables came in at $4.3 million in Q4 2022.
Intensity Therapeutics (INTS) Notes Payables (2022) Analysis & Trends
Intensity Therapeutics (INTS) has 1 years of Notes Payables data on file, last reported at $4.3 million in Q4 2022.
- Quarterly Notes Payables changed N/A year-over-year to $4.3 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $4.3 million (changed N/A YoY) and the FY2022 annual result came in at $4.3 million, changed N/A from the prior year.
- Notes Payables held at $4.3 million in Q4 2022.
- In the past five years, Notes Payables ranged from a high of $4.3 million in Q4 2022 to a low of $4.3 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - |
| 10 | Intensity Therapeutics | 12.80 Mn | 12.80 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 4.35 Mn |